期刊
ACS CHEMICAL NEUROSCIENCE
卷 10, 期 2, 页码 783-791出版社
AMER CHEMICAL SOC
DOI: 10.1021/acschemneuro.8b00313
关键词
Adenosine receptor; antagonist; Parkinson's disease; GPCR
资金
- National Natural Science Foundation of China [81773561, 81473090, 81773702, BM2013003]
- PAPD
- (Priority Academic Program Development of Jiangsu Higher Education Institutions)
Parkinson's disease (PD) is a neurodegenerative disease with significant unmet medical needs. The current dopamine-centered treatments aim to restore motor functions of patients without slowing the disease progression. Long-term usage of these drugs is associated with diminished efficacy, motor fluctuation, and dyskinesia. Furthermore, the nonmotor features associated with PD such as sleep disorder, pain, and psychiatric symptoms are poorly addressed by the dopaminergic treatments. Adenosine receptor A(2A) antagonists have emerged as potential treatment for PD in the past decade. Here we summarize the recent work (2015-2018) on adenosine receptor A(2A) antagonists and discuss the challenge and opportunity for the treatment of PD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据